Recombinant erythropoietin - Bio-Ker
Latest Information Update: 25 Sep 2013
At a glance
- Originator Bio-Ker
- Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 11 Sep 2013 Investigation in Undefined indication in Italy (Parenteral)